MEDIVOLVE

INVESTOR PRESENTATION

JANUARY 1st, 2021

DISCLAIMER

This presentation of Medivolve Inc. ("Medivolve" or the "Company") is for informational purposes only and does not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities of the Company. The information contained herein is subject to change without notice and is based on publicly available information, internally developed data and other sources. Where any opinion or belief is expressed in this presentation, it is based on the assumptions and limitations mentioned herein and is an expression of present opinion or belief only. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information. The Company disclaims and excludes all liability (to the extent permitted by law), for losses, claims, damages, demands, costs and expenses of whatever nature arising in any way out of or in connection with the information in this presentation, its accuracy, completeness or by reason of reliance by any person on any of it. This presentation should not be construed as legal, financial or tax advice to any individual, as each individual's circumstances are different. Readers should consult with their own professional advisors regarding their particular circumstances.. An investment in the securities of Medivolve is speculative and involves a number of risks that should be considered by a prospective investor.

The information contained in this presentation is not directed to persons or entities resident in the United States and does not constitute an offer or solicitation by anyone in the United States or in any other jurisdiction in which such an offer or solicitation is not authorized or to any person to whom it is unlawful to make such an offer or solicitation, unless otherwise exempt from United States securities legislation. This presentation does not constitute an offer of securities, and no offer or sale of securities will be conducted in any jurisdiction in which such offer or sale is prohibited.

THE SECURITIES DESCRIBED IN THE PRESENTATION HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933 (THE "SECURITIES ACT"), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. AND THE SECURITIES MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE OR LOCAL SECURITIES LAWS.

This presentation includes market and industry data that has been obtained from third party sources. The Company believes that the industry data is accurate and that the estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, the Company has not independently verified any of the data from third party sources referred to in this presentation or ascertained the underlying assumptions relied upon by such sources. References in this presentation to research reports, results of clinical trials or to articles and publications should be not construed as depicting the complete findings of the entire referenced report or article.

FORWARD-LOOKING STATEMENTS

Certain statements in this presentation are "forward-looking statements" or "forward-looking information" within the meaning of applicable securities laws (collectively, "forward-looking statements"). Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always using words or phrases such as "expect", "seek", "endeavour", "anticipate", "plan", "estimate", "believe", "intend", or stating that certain actions, events or results may, could, would, might or will occur or be taken, or achieved) are not statements of historical fact and may be "forward-looking statements", including, without limitation, statements pertaining to the global market opportunity for testing kits, the Company's expansion plans and the timing thereof, the price at which testing kits may be sold and expected margins, regulatory approval for the use of testing kits and the Company's long-term opportunities. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made and involve significant known and unknown risks, uncertainties and assumptions which could cause actual results or events to differ materially from those presently anticipated. Such assumptions include, without limitation, the Company partnering with established medical distribution companies, the use of testing kits will receive regulatory approval, market acceptance of testing kits and businesses and other organizations will require large-scale testing protocols. A number of factors could cause actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, competition in the market, the Company failing to obtain necessary regulatory approvals, the Company electing not to proceed with its expansion plans or not having the necessary funds to do so and the Company not being able to secure maintain appropriate distribution partnerships. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements could vary materially from those expressed or implied by the forward-looking statements contained in this presentation. Investors should not place undue reliance on these forward-looking statements. Because of the risks, uncertainties and assumptions contained herein, forward-looking statements should not be read as guarantees of future performance or results. Nothing in this presentation is, or should be relied upon as, a promise or representation as to the future. Although the forward-looking statements contained in this presentation are based upon what the Company's management currently believes to be reasonable assumptions, the Company makes no assurances that actual results, performance or achievements will be consistent with these forward-looking statements. The forward-looking statements in this presentation are made as of the date of this presentation. Except as required by law, the Company does not have any obligation to advise any person if it becomes aware of any inaccuracy in or omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to reflect new events or circumstances.

MEDIVOLVE

MEDIVOLVE INVESTMENT OVERVIEW

Medivolve is a publicly traded company that seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors.

With a seasoned executive team and renowned global advisors that provide expertise across industries, **Medivolve offers investors a diversified investment in the COVID-19 medical space across geographic regions and three focus areas:** detection, prevention, and treatment.

TICKERS:		
NEO: MEDV	Shares Outstanding	149.8 M
OTC:COPRF	Options Weighted average price: $0.21	14.7 M
FRA:34C1	Warrants	16.1 M
	Market Capitalization (CAD) as of January 1st, 2020	$72.2 M

MEDIVOLVE

COVID-19 INVESTMENT HIGHLIGHTS

Medivolve has identified the COVID-19 testing economy as the most lucrative opportunity:

Wells Fargo forecasts a U.S. COVID-19 testing market(1) of

US$157 billion

"We've gone from 1 million to 4.5 million tests per week in the U.S., but we'll need to redouble our efforts to make it to 30 million tests per week and beyond in order to reopen communities and economies and keep them open."

– The Rockefeller Foundation

A COMPLETE COVID-19 TESTING SOLUTION

- Wholly owned subsidiary Collection Sites is rolling out over 740 COVID-19 testing sites across the U.S. with partners including Simon Property Group, Brookfield, Sandor, H&S Energy Products, among others.
- Collection Sites provides quick and convenient COVID-19 testing in conjunction a CLIA registered lab, including rapid antigen, PCR and rapid antibody tests with insurance coverage options.

(1) Wells Fargo Total Addressable Market (TAM) based on aggregate revenue estimates for the U.S. only between 2020E – 2022E. Includes COVID testing labs and suppliers (Aug 16, 2020).
Source: The Rockefeller Foundation, The U.S. Department of Health and Human Services (HSS), broker analyst research

MEDIVOLVE

SUBSTANTIAL UPSIDE PER SITE

Average Price Per Test: US$95

Estimated Max Tests Per Hour: 15

Average Hours Per Day: 10

Highly profitable with projected EBITDA margins over 55%

Potential Monthly Revenue:

US$428K

COLLECTION SITES - NATIONAL FOOTPRINT



2021 Rollout:

- Operational sites – 32 Sites
- **Pending Installation:**
  - **Phase 1: +13 Sites**
  - **Phase 2: +62 Sites**
  - **Phase 3: +70 Sites**

New sites targeting high-population centres

740+ Sites Under Contract

MEDIVOLVE

EXCEPTIONAL LEADERSHIP

We make decisions based on world renowned expertise

DOUGLAS SOMMERVILLE

CEO

Doug has held prominent roles at pharmaceutical giants such as Teva Pharmaceuticals and Baxter Healthcare International. In this role as Head of Teva Canada, Mr. Sommerville was responsible for Teva's third largest global subsidiary, with sales in excess of $1.3 billion. Doug was also the Chairman of the Canadian Generic Pharmaceutical Association up until his retirement from Teva Canada in 2018. He holds an MBA from the Schulich School of Business.

Dr. GLENN COPELAND

ADVISOR

Possessing over 45 years of experience in both orthopaedic treatment and sports medicine, Dr. Glenn Copeland is one of North America's most prominent foot and ankle specialists. Between 2002 and 2008, Dr. Copeland was selected to be the founder, chairman, and CEO of Cleveland Clinic Canada. Cleveland Clinic is universally regarded as one of the top three medical institutions in the world.



Dr. JOSEPH SUGERMAN

ADVISOR

Dr. Sugerman is a board-certified otolaryngologist who manages a private practice in Los Angeles focused on the management of voice disorders. He is a past Clinical Chief at Cedars-Sinai Medical Centre. He is also a former board member of MGM Mirage. Dr. Sugerman was a Clinical Instructor at the University of Southern California (USC) Keck School of Medicine and the University of California at Los Angeles (UCLA) Department of Otolaryngology: Head and Neck Surgery Division.

Dr. LAWRENCE STEINMAN

ADVISOR

Dr. Steinman is Professor of Neurology, Neurological Sciences and Paediatrics at Stanford University and was Chair of the Stanford Program in Immunology from 2001 to 2011. His research focuses on antigen specific tolerance in autoimmune disease and in gene therapy for degenerative neurologic diseases. Dr. Steinman has elucidated what provokes relapses and remissions in multiple sclerosis (MS). He serves as attending neurologist at Stanford's Lucille Packard Children's Hospital.


MEDIVOLVE
INVESTMENTS: STANDARDS &
TESTING SOLUTIONS
EURO2016
adidas
BEAU JEU

MEDIVOLVE

RESTORING REALITY RESPONSIBLY

STANDARD FOR SAFE OPERATION: GLENCO MEDICAL CORP.

Through Glenco Medical, a 30% owned subsidiary, Medivolve is helping develop and implement a series of protocols for businesses and people to return to normal operation in a COVID-19 environment.

These standards can provide users a sense of security that differentiates Medivolve's COVID-19 testing solutions.

The Standards are created from decades of experience by Dr. Glenn Copeland and his company Glenco Medical Corp. with assistance from Dr Steinman (immunology expert), This partnership and the associated protocols compliment other Medivolve partnerships and augments our COVID-19 testing solution.

Glenco Medical recently established the COVID-19 Standard for Safe Sport, Industry, and Retail, through which it is developing and implementing protocols to safely return sports players, businesspeople, performers and shoppers to their respective professions and passions.

MEDIVOLVE

RESTORING REALITY RESPONSIBLY

MINING CASE STUDY: KINROSS GOLD

QuestCap has partnered with a subsidiary of Kinross Gold, to provide a comprehensive COVID-19 testing solution for employees at its Russian operations.

Specifically, QuesCap provided assorted tests and analyzers to be used along with proprietary standards developed by Glenco Medical. The total contract value was US$2.1 million.

The miners are tested for COVID-19 upon entry and throughout their 6-week work rotations, helping prevent any spread of the virus among workers and minimize operational downtime for Kinross Gold.

COVID-19 RT-PCR and antibody testing for individuals and staff by trained and certified clinicians.

Self-reporting, identification of tested, aggregation of test results and collaboration with governing bodies.

Self-regulation, by enforcing medical recommendations and measures for recovery.

Digital ID verification, authentication and credential management through a digital app.

Contact tracing in order to help identify, educate, and monitor the spread and impact of the virus.

MEDIVOLVE

SANATY IPS – CLINICS & TESTING

Medivolve acquired a 28% indirect equity interest in Sanaty IPS, a government designated health providing institution that provides medical consultation and diagnostic services in Colombia.

Sanaty's currently has two operating clinics in Cucuta and Bogota, in Colombia with plans to launch three additional clinics by 2021 . This will yield an aggregate maximum daily testing capacity of 1,500 PCR tests and 6,000 antibody tests.

A TELEMEDICINE SOLUTION

Sanaty is authorized by the Ministry of Health to provide its services via telemedicine, allowing for long-distance patient and clinician contact. During the COVID-19 pandemic and due to the strict Colombian quarantine, Sanaty has been serving patients virtually and prescribing both real-time reverse transcription polymerase chain reaction (rRT-PCR) and antibody tests for COVID-19.

COLLECTION SITES

COVID-19 TESTING SOLUTION

MEDIVOLVE

COLLECTION SITES AT A GLANCE

CollectionSites
Flattening the curve

A complete and versatile solution for the ultra-high demand COVID-19 testing marketing in the U.S.

1. COVID-19 testing in ultra-high demand

   Potential need for 30 million tests per week[1] in the U.S.

2. Mobile Pop-Up sites for **8-10 minute** RT-PCR, antigen and antibody testing

3. Same-day results from certified high complexity Alcala Labs - 98% accuracy

4. **740+ locations** throughout the US contracted: Shopping malls, convenience stores and gas stations

5. Up to 150 tests per cube per day at an affordable US$100 per test

6. Highly profitable with projected EBITDA margins over **55%**

Pop-Up Sites

Mobile 100 sqft COVID-19 testing centres to in over 645 high foot traffic locations nationwide.

(1) The Rockefeller Foundation

MEDIVOLVE

COVID-19 TESTING PRICING

Stable pricing but very strong need for affordable testing

Prices for COVID-19 Diagnostics Tests

(Peterson KFF Health Tracker)



- *Median price for testing was US$127*
- *One in five tests are more than US$200*

"The American Clinical Laboratory Association estimates that its members, which have run a collective 11 million coronavirus tests, charge between $95 and $209."

*– **New York Times** (Jun 2020)*

More affordable COVID-19 testing prices critical to reaching Rockefeller's 30 million test per week recommendation

Collection Sites one-stop-shop mobile testing centres starting at US$60 per test provides the U.S. with a compelling nationwide solution to more affordable testing

Source: Peterson KFF, New York Times, The Rockefeller Foundation

MEDIVOLVE

POP-UP sites OVERVIEW

Convenient rapid testing centres with certified lab results

- Collection Sites Pop-Up sites provides mobile and convenient COVID-19 testing with insurance coverage options
- 8-10 minutes to administer antibody, antigen and RT-PCR tests
- Average price of US$100 per test
- Same-day results returned via text or email performed by partner Alcala Labs with 98% accuracy

Appointments and payments are handled through an online portal www.testbeforeyougo.com

BE A PART OF THE SOLUTION
TEST BEFORE YOU GO
TESTBEFOREYOUGO.COM

Profile of a Standard Pop-Up Cube

- ✓ Mobile testing sites
- ✓ 100 sqft footprint
- ✓ Insured with no liability to retailer
- ✓ Weekly rental payment for space
- ✓ Testing done by CLIA certified lab Alcala

MEDIVOLVE

NATIONWIDE FOOTPRINT

Poised to become the leading affordable COVID-19 testing solution in the U.S.

Over 300 Pop-Up sites and counting to be installed across the U.S. in partnerships with major property groups in high-traffic locations

Property Partner	Locations
Simon Group	165
Brixmor	340
Sandor	65
Brookfield Malls	73
Other (H&S, Tanger, etc.)	100+
Total	**743+**

Pop-Up sites Footprint



Nationwide Property Partners: SIMON™ Brookfield

MEDIVOLVE

COVID-19 TESTING: ANTIBODY, RT-PCR & ANTIGEN

Patients enter the Pop-Up sites and can access three different types of COVID-19 testing:

1 Rapid Antibody Blood Test

- Antibody (Serology) tests look for SARS-CoV-2 IgM & IgG antibodies(1) in the blood to determine if there was a **past infection**
- A blood sample is taken with immediate results provided, but will also be sent to a lab for certified testing results
- **What does a positive test result mean?**
  - A positive test means the person ***was*** infected with COVID-19 in the past and their immune system developed antibodies to try to fight it off

2 RT-PCR Test

- RT-PCR tests are real-time reverse transcription polymerase chain reaction tests that look for SARS-CoV-2 virus genetic material to determine if the person has an **active infection**
- A nasal or throat swab is taken by a healthcare provider and tested
  - Swabs are sent to a lab for testing results
- **What does a positive test result mean?**
  - A positive RT-PCR test means that the person being tested has an ***active*** COVID-19 infection

3 Antigen Test

- Antigen tests look for pieces of proteins that make up the SARS-CoV-2 virus to determine if the person has an **active infection**
- In most cases, a nasal or throat swab is taken by a healthcare provider and tested
  - Swabs are sent to a lab for testing results
- **What does a positive test result mean?**
  - A positive antigen test means that the person being tested has an **active** COVID-19 infection

(1) Antibodies are formed by the body to fight off infections. Immunoglobulin M (IgM) is the first antibody that is formed against a germ, so it appears on tests first, usually within 1-2 weeks. The body then forms immunoglobulin G (IgG), which appears on tests about 2 weeks after the illness starts. IgM usually disappears from the blood within a few months, but IgG can last for years.

Source: HHS

MEDIVOLVE

COVID-19 TESTING – HOW IT WORKS

1 Rapid Antibody Blood Test

Finger Prick

Remove protective cap from the blue needle and pierce the tip of your finger.

Squeeze your finger to produce enough blood for two drops.

Test Card

Collect blood with disposable dropper provided. Release **TWO** drops of blood in the bottom collection area of the test card, followed by **TWO** drops of the Diluent

2 RT-PCR Test

1. Samples are collected from the nose or throat of a patient using a swab and are mixed with chemical reagents

2. Samples are put in a machine that duplicates the genetic material and detects its presence



3 Antigen Test

Procedure

1 Peel off aluminum foil seal and rotate the swab inside the extraction vial vigorously at least 5 times



2 Remove the swab, close the vial by pushing the cap onto the vial and squeeze the vial gently to release 3 drops of sample to the sample well

- Patients are assisted by lab assistants in administering tests which can take 8-10 minutes
- Once tests are performed, patients can leave the facilities while samples are sent to certified Alcala Labs
- After testing, Collection Sites transfers communication and customer service responsibilities to Alcala Labs including follow-up of results with patients

MEDIVOLVE

STRATEGIC DIAGNOSTICS PARTNER

Alcala is a fully registered and licensed laboratory under the laws and requirements of California, located in San Diego

- Provides access to the most accurate testing platforms and Return to Work (RTW) algorithms technology available
- Ensures the most accurate and reliable results for patients
- State-of-the-art IT platform created to manage all aspects of third-party administration

Proven Alcala System

Customized Approach

- Determine the needs of an organization and resources necessary to execute

Test Collection

- Execute: an onsite or multi-location process to effective specimen collection

Result Reporting

- A single platform provides access to employee testing data, customized HR reports

Manage Process

- Assist company with RTW protocol implementation and manage all aspects

MEDIVOLVE

TEAM

MEDIVOLVE

STRATEGIC ADVISORS

MICHAEL MCCARTHY

Mike is widely recognized across Canada as a health care champion and advocate. As a principal with Grosso McCarthy, Mike has over 15 years of experience with the Ontario Ministry of Health and Long Term Care, and over 25 years in health policy and delivery. In 2001, he was appointed Senior Policy Advisor to the Ontario Minister of Health. Mike has also been on the front lines of health care, working for 18 years as a psychiatric nurse



JIM ROGERS

Mr. Rogers co-founded the Quantum Fund, a global-investment partnership. After retiring - at age 37, Mr. Rogers continued to manage his own portfolio and serve as a professor of finance at the Columbia University Graduate School of Business. Mr. Rogers also presciently saw the formation of the subprime mortgage crisis a year before it erupted

MIKE MANCIAS

Mike has served as the Chief Performance Advisor to LeBron James for over 14 years and counting. His experience includes working with NBA, NFL, MLB, PGA, and top NCAA athletes. Mike attended the University of Texas-Pan American and graduated with a degree in Health Education. Mike is licensed and nationally certified by the Accredited National athletic Trainers Association and is a 14-year member of The National Basketball Athletic Trainers Association.

RICHARD DOLAN

Richard is an advocate and researcher on the subject of human betterment through effective and responsible investment. An internationally best-selling author and highly sought after speaker, Richard has shared the stage with the likes of Presidents Bill Clinton, George W. Bush, Barack Obama and Donald J. Trump.

MEDIVOLVE

DIRECTORS & OFFICERS

DOUGLAS SOMMERVILLE

CEO, DIRECTOR

Doug has held prominent roles at pharmaceutical giants such as Teva Pharmaceuticals and Baxter Healthcare International. In this role as Head of Teva Canada, Mr. Sommerville was responsible for Teva's third largest global subsidiary, with sales in excess of $1.3 billion. Doug was also the Chairman of the Canadian Generic Pharmaceutical Association up until his retirement from Teva Canada in 2018. He holds an MBA from the Schulich School of Business.

DANIYAL BAIZAK

DIRECTOR

- Financial and strategic advisor on M&A
- Experience in Central Asian and Russian markets

DEBORAH BATTISTON

CFO

- CPA, CGA
- ICD.D, Rotman School of Management
- 25 years of financial management

WEN YE

DIRECTOR

- CPA, CGA and holds a Bachelor of Commerce degree from Laurentian University.
- 17+ years of finance management experience in the mining, securities and logistics sectors.

AARON ATIN

CORPORATE SECRETARY

- J.D., University of Toronto
- Corporate and securities lawyer

DR. BEVERLEY RICHARDSON

DIRECTOR

- Decades of experience as psychotherapeutic practitioner and with behavioural health programs
- Doctorate Degree in Psychology, Registered Clinical Counsellor, Internationally Certified Eating Disorder Specialist, and EMDR Level II Trauma Therapist..

INQUIRIES

Douglas Sommerville, CEO

Contact: Doug.Sommerville@medivolve.ca

DISCLAIMER – RECISION RIGHTS

In certain circumstances, purchasers resident in certain provinces of Canada are provided with a remedy for rescission or damages, or both, in addition to any other rights they may have at law, where an offering memorandum (such as this presentation) and any amendment to it contains a misrepresentation. Where used herein, "misrepresentation" means an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make any statement not misleading in light of the circumstances in which it was made. These remedies, or notice with respect to these remedies, must be exercised or delivered, as the case may be, by the purchaser within the time limits prescribed by applicable securities legislation.

The following summary is subject to the express provisions of the applicable securities laws, regulations and rules, and reference is made thereto for the complete text of such provisions. Such provisions may contain limitations and statutory defenses not described here on which Medivolve Inc. (the "Company") and other applicable parties may rely. Purchasers should refer to the applicable provisions of the securities legislation of their province for the particulars of these rights or consult with a legal adviser.

The following is a summary of rights of rescission or damages, or both, available to purchasers resident in the province of Ontario, New Brunswick, Nova Scotia and Saskatchewan. If there is a misrepresentation herein and you are a purchaser under securities legislation in Ontario, New Brunswick, Nova Scotia and Saskatchewan you have, without regard to whether you relied upon the misrepresentation, a statutory right of action for damages, or while still the owner of the securities, for rescission against the Company. This statutory right of action is subject to the following: (a) if you elect to exercise the right of action for rescission, you will have no right of action for damages against the Company; (b) except with respect to purchasers resident in Nova Scotia, no action shall be commenced to enforce a right of action for rescission after 180 days from the date of the transaction that gave rise to the cause of action; (c) no action shall be commenced to enforce a right of action for damages after the earlier of (i) 180 days (with respect to purchasers resident in Ontario) or one year (with respect to purchasers resident in Saskatchewan and New Brunswick) after you first had knowledge of the facts giving rise to the cause of action and (ii) three years (with respect to purchasers resident in Ontario) or six years (with respect to purchasers resident in Saskatchewan and New Brunswick) after the date of the transaction that gave rise to the cause of action; (d) with respect to purchasers resident in Nova Scotia, no action shall be commenced to enforce a right of action for rescission or damages after 120 days from the date on which payment for the securities was made by you; (e) the Company will not be liable if it proves that you purchased the securities with knowledge of the misrepresentation; (f) in the case of an action for damages, the Company will not be liable for all or any portion of the damages that it proves do not represent the depreciation in value of the securities as a result of the misrepresentations; and (g) in no case will the amount recoverable in such action exceed the price at which the securities were sold to you. The foregoing is a summary only and is subject to the express provisions of the Securities Act (Ontario), the Securities Act (New Brunswick), the Securities Act (Nova Scotia) and the Securities Act (Saskatchewan), and the rules, regulations and other instruments thereunder, and reference is made to the complete text of such provisions contained therein. Such provisions may contain limitations and statutory defenses on which the Company may rely.

In Manitoba, the Securities Act (Manitoba), in Newfoundland and Labrador the Securities Act (Newfoundland and Labrador) and in Prince Edward Island the Securities Act (PEI) provide a statutory right of action for damages or rescission to purchasers resident in Manitoba, Newfoundland and PEI, respectively, in circumstances where this presentation or an amendment hereto contains a misrepresentation, which rights are similar, but not identical, to the rights available to Ontario purchasers.

Notwithstanding that the Securities Act (British Columbia), the Securities Act (Alberta), and the Securities Act (Québec) do not provide, or require the Company to provide, to purchasers resident in these jurisdictions any rights of action in circumstances where this presentation or an amendment hereto contains a misrepresentation, the Company hereby grants to such purchasers contractual rights of action that are equivalent to the statutory rights of action set forth above with respect to purchasers resident in Ontario.